Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

A clinical study of belzutifan for treatment of kidney cancer (MK-6482-013) Ended

2022-502123-21-00 Advanced Renal Cell Carcinoma 4 2020-12-08
The study of Trastuzumab Deruxtecan to assess its efficacy, safety and tolerability in Patients with Selected HER2 Expressing Tumors Ended

2023-504721-39-02 HER2 Expressing Tumors 4 2020-12-07
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Pa… Ended

2023-506911-16-00 ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVAN 5 2020-12-04
Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera M… Ended

2024-514468-26-00 Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF 9 2020-12-04
Comparison of two strategies that use the same drugs but with inverted sequence for the treatment of patients with metastatic colorectal can… Ended

2024-513296-41-00 Colorectal cancer spread at distance, RAS BRAF wild typ 4 2020-12-03
Study of Trastuzumab Deruxtecan (DS-8201a, T-DXd) versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Ca… Ended

2024-516653-44-00 HER2-Low, Hormone Receptor Positive Breast Cancer which 5 2020-11-30
To assess the relative BA of a low-strength FDC tablet formulation of niraparib plus AA compared to niraparib and AA co-administered as sing… Ended

2023-508150-26-00 Metastatic castration-resistant prostate cancer (mCRPC) 2 2020-11-26
A Phase 1/2, first-in-human, two-part, open-label clinical trial of intravenous administration of CTL-002 given as monotherapy and/or in com… Ended

2024-512575-12-00 ADVANCED-STAGE, RELAPSED/REFRACTORY SOLID TUMORS 9 2020-11-25
A Combination of Acalabrutinib with R-CHOP in Subjects with previously untreated non-GCB DLBCL Ended

2023-509358-72-00 Diffuse large B-cell lymphoma 5 2020-11-23
Safety and Efficacy Study of Epcoritamab in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome Ended

2023-504828-25-00 Chronic Lymphocytic Leukemia 9 2020-11-16
Apalutamide, Radiotherapy and LHRH Agonist in High-Risk Hormone-Sensitive Prostate Cancer Patients Assessed by PSMA-PET Ended

2023-505852-23-00 High risk recurrent prostate cancer previously treated 5 2020-11-12
Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Sub… Ended

2023-508281-15-00 Locally Advanced or Metastatic Solid Tumors 1 2020-11-10
A study of tucatinib vs. placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with advanced or metastatic HER2+ breast… Ended

2024-514733-38-00 Unresectable locally-advanced or metastatic HER2+ breas 5 2020-11-03
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients with Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung… Ended

2024-511185-37-00 Completely resected stage I or IIA non-squamous non-sma 6 2020-11-03
Loc-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction tr… Ended

2024-515331-30-00 Primary Central Nervous System Lymphoma (PCNSL) 7 2020-10-30
This study will evaluate the safety, tolerability, and pharmacokinetics of Runimotamab administered intravenously as a single agent and in c… Ended

2023-504491-15-00 Human epidermal growth factor receptor (HER2)-Expressin 1 2020-10-30
Post-operative adjuvant treatment for HPV-positive tumours Ended

2024-516673-68-00 Human papillomavirus (HPV)-positive oropharyngeal cance 5 2020-10-27
A Study of Atezolizumab with or without Tiragolumab in Participants with Unresectable Esophageal Squamous Cell Carcinoma whose Cancers have … Ended

2022-502052-30-00 Unresectable Esophageal Squamous Cell Carcinoma 5 2020-10-27
Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended

2023-510390-33-00 HER2-negative breast cancer patients with high relapse 5 2020-10-23
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) Ended

2023-504805-35-00 Lymphoma of B-cell origin 9 2020-10-22
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refra… Ended

2023-505659-27-00 Multiple Myeloma 4 2020-10-21
Treatment of advanced-stage malignancies harboring BRAF mutations with combination of Sorafenib and Trametinib: a multicenter study Ended

2024-512887-77-00 advanced-stage malignancies harboring BRAF mutations wi 9 2020-10-21
An open study for participants who have been on darolutamide treatment in any other Bayer study Ended

2022-502084-38-00 Cancer 5 2020-10-16
A Phase 3 Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment … Ended

2023-506365-64-00 Deleterious Germline or Somatic Homologous Recombinatio 5 2020-10-16